HitGen Ltd. Collaborates With Johnson & Johnson Innovation for the Discovery of New Oncology, Metabolics Therapies

Chengdu, China, September 21, 2016 (Newswire.com) - HitGen Ltd., a privately held biotech company focused on technology for effective and efficient molecular discovery, announced today a multi-target global collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has been facilitated by Johnson & Johnson Innovation. This collaboration is to discover potential new therapies in areas of strategic interest to Janssen, especially in the areas of oncology and metabolics.

As part of the agreement, HitGen’s technology platform, centered around design, synthesis, screening, and hit validation, will be deployed to find new small-molecule hits and leads for therapeutic targets identified by Janssen. Within the scope of this collaboration, HitGen will provide biology, chemistry and screening to support Janssen discovery efforts.

“We are excited to collaborate with Janssen as a strategic partner for these discovery efforts,” said Dr. Jin Li, Chairman & CEO of HitGen Ltd. He added that “HitGen continues to grow as a world-class drug discovery organization. We are keenly focused on working with our partners to provide new solutions for unmet medical needs.”

About HitGen Ltd

HitGen is an innovation driven life-sciences company based in Chengdu, China. HitGen has established a unique platform for early drug discovery research. Our DNA encoded libraries contain over 6 billion drug-like compounds with immense diversity. The library is populated with over hundreds of distinct chemical scaffolds, with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes.

For further information, please contact

Dr Jin Li, Chairman & CEO， HitGen Ltd. Tel: +86 028 85197385

Dr Bill Farley, VP, Business Development， HitGen Ltd. Tel: +1 516 318 2150

www.hitgen.com

Source: HitGen Ltd